keyword
MENU ▼
Read by QxMD icon Read
search

high dose methotrexate

keyword
https://www.readbyqxmd.com/read/27888882/the-challenge-of-primary-central-nervous-system-lymphoma
#1
REVIEW
Julia Carnevale, James L Rubenstein
Primary central nervous system (CNS) lymphoma is a challenging subtypes of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27888881/central-nervous-system-prophylaxis-for-aggressive-b-cell-lymphoma-who-what-and-when
#2
REVIEW
Norbert Schmitz, Maike Nickelsen, Kerry J Savage
Central nervous system (CNS) relapse of aggressive B-cell lymphoma is a rare but serious complication with poor survival. Different approaches have been used to define risks factors for CNS relapse and establish prophylactic measures. Although patients with low or intermediate risk of CNS relapse should not undergo special diagnostic or therapeutic measures, CNS MRI as well as cytology and flow cytometry of the cerebrospinal fluid are suggested for high-risk patients (and patients with testicular involvement) at diagnosis, and prophylactic high-dose methotrexate in patients without proven CNS involvement...
December 2016: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/27867930/a-case-of-primary-central-nervous-system-lymphoma-located-at-brain-stem-in-a-child
#3
Jinho Kim, Young Zoon Kim
Primary central nervous system lymphoma (PCNSL) is an extranodal Non-Hodgkin's lymphoma that is confined to the brain, eyes, and/or leptomeninges without evidence of a systemic primary tumor. Although the tumor can affect all age groups, it is rare in childhood; thus, its incidence and prognosis in children have not been well defined and the best treatment strategy remains unclear. A nine-year old presented at our department with complaints of diplopia, dizziness, dysarthria, and right side hemiparesis. Magnetic resonance image suggested a diffuse brain stem glioma with infiltration into the right cerebellar peduncle...
October 2016: Brain Tumor Research and Treatment
https://www.readbyqxmd.com/read/27863767/stroke-like-encephalopathy-following-high-dose-intravenous-methotrexate-in-an-adolescent-with-osteosarcoma-a-case-report
#4
Daniel Almeida do Valle, Fabiana Maria Kakehasi, Roberta Maria Pereira Albuquerque de Melo, Claudia Machado Siqueira, Thaiane Ferreira Soares, Karla Emilia de Sá Rodrigues
No abstract text is available yet for this article.
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27861204/tumor-necrosis-factor-alpha-inhibitor-etanercept-does-not-alter-methotrexate-induced-gastrointestinal-mucositis-in-rats
#5
Nicoline S S Kuiken, Edmond H H M Rings, Jan-Willem C Alffenaar, Rick Havinga, Angelika Jurdzinski, Albert K Groen, Wim J E Tissing
OBJECTIVES: Gastrointestinal (GI) mucositis is a severe side effect of chemotherapy and radiotherapy. Pro-inflammatory cytokines are thought to play an important role in the pathophysiology of GI mucositis. We aimed to determine the effect of the Tumor Necrosis Factor-alpha (TNF-α) inhibitor Etanercept on the severity of mucositis in a previously established methotrexate (MTX)-induced GI mucositis rat model. METHODS: Male Wistar rats received 60 mg/kg MTX at day 0 iv...
November 18, 2016: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27860222/late-outcomes-of-adult-survivors-of-childhood-non-hodgkin-lymphoma-a-report-from-the-st-jude-lifetime-cohort-study
#6
Matthew J Ehrhardt, John T Sandlund, Nan Zhang, Wei Liu, Kirsten K Ness, Nickhill Bhakta, Wassim Chemaitilly, Kevin R Krull, Tara M Brinkman, Deborah B Crom, Larry Kun, Sue C Kaste, Gregory T Armstrong, Daniel M Green, Kumar Srivastava, Leslie L Robison, Melissa M Hudson, Daniel A Mulrooney
BACKGROUND: Survivors of childhood non-Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors. METHOD: Chronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data...
November 15, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27854097/optimizing-the-delivery-of-antineoplastic-therapies-to-the-central-nervous-system
#7
REVIEW
Jarushka Naidoo, Hardik Panday, Sadhana Jackson, Stuart A Grossman
Despite significant advances in the treatment of systemic cancers, progress in the treatment of primary brain tumors has been quite modest. In addition, an increasing proportion of patients with systemic cancers are presenting with brain-only metastases. These observations highlight the critical role that the blood-brain barrier plays in preventing antineoplastic therapies from reaching the central nervous system in therapeutic concentrations. This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain...
November 15, 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27843136/high-dose-methotrexate-based-immuno-chemotherapy-for-elderly-primary-cns-lymphoma-patients-primain-study
#8
K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Löw, M Binder, J Atta, U Keller, H-H Wolf, S W Krause, G Heß, R Naumann, S Sasse, C Hirt, M Lamprecht, U Martens, A Morgner, J Panse, N Frickhofen, A Röth, C Hader, M Deckert, H Fricker, G Ihorst, J Finke, G Illerhaus
To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma (PCNSL), we conducted a multicentre single arm trial. One cycle consisted of rituximab (375 mg/m(2), day 1, 15, 29), high-dose methotrexate (3 g/m(2) days 2, 16, 30), procarbazine (60 mg/m(2) day 2-11), and lomustine (110 mg/m(2), day 2)-R-MPL protocol. Due to infectious complications we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol...
November 15, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27822085/danish-childhood-cancer-registry
#9
REVIEW
Henrik Schrøder, Catherine Rechnitzer, Peder Skov Wehner, Steen Rosthøj, Jens Kjølseth Møller, Birgitte Lausen, Gitte Petersen, Mette Nørgaard
AIM OF DATABASE: The overall aim is to monitor the quality of childhood cancer care in Denmark; to register late effects of treatment; to analyze complications of permanent central venous catheters (CVCs); to study blood stream infections in children with cancer; and to study acute toxicity of high-dose methotrexate infusions in children with leukemia. STUDY POPULATION: All children below 15 years of age at diagnosis living in Denmark diagnosed after January 1, 1985 according to the International Classification of Diseases 10, including diagnoses DC00-DD48...
2016: Clinical Epidemiology
https://www.readbyqxmd.com/read/27821230/-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-a-clinicopathologic-and-molecular-study
#10
Z P Ma, Babayi Ainiwaer, Z Y Liu, X L Shi, W L Cui, W Zhang, X X Li
Objective: To investigate clinicopathologic characteristics, immunophenotype and EB virus-related molecular genetic alterations in primary central nervous system diffuse large B cell lymphoma (DLBCL) along with correlation with clinical prognosis. Methods: A total of 30 cases of primary central nervous system DLBCL were retrospectively studied by retrieving clinical data, histological evaluation and immunophenotyping by EnVision two steps methods. The expression of EBER mRNA was detected by in situ hybridization and bcl-2, bcl-6 and C-MYC gene abnormalities were analyzed by interphase fluorescence in situ hybridization...
November 8, 2016: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/27820134/using-a-bedside-algorithm-to-individually-dose-high-dose-methotrexate-for-patients-at-risk-for-toxicity
#11
Jennifer H Foster, Melanie B Bernhardt, Patrick A Thompson, E OʼBrian Smith, Eric S Schafer
We developed a bedside algorithm for individually adjusting the high-dose methotrexate (HDMTX) dose (5 g/m) given to patients with acute lymphoblastic leukemia at high risk for methotrexate toxicity. Data were reviewed for 8 patients receiving 21 cycles of HDMTX as per our algorithm. Eleven cycles began with 5 g/m, 10 cycles began with a preinfusion 20% to 25% dose reduction. Neither mean MTX AUC (2320.5±179.1 vs. 2080.4±161.7 μmol×h/L), mean Cpss (64.3±7.9 vs. 60.8±6.1 μM), nor toxicities were statistically different between groups...
November 4, 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/27807492/novel-brentuximab-vedotin-combination-therapies-show-promising-activity-in-highly-refractory-cd30-non-hodgkin-lymphoma-a-case-series-and-review-of-the-literature
#12
Wilfred Delacruz, Robert Setlik, Arash Hassantoufighi, Shyam Daya, Susannah Cooper, Dale Selby, Alexander Brown
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The first is a patient with stage IV anaplastic large cell lymphoma (ALCL) with cranial nerve involvement who failed front-line treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) and second line cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate (MTX), and cytarabine (hyperCVAD) with intrathecal- (IT-) MTX and IT-cytarabine, but responded when BV was substituted for vincristine (hyperCBAD)...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/27801773/chemotherapy-associated-posterior-reversible-encephalopathy-syndrome-a-case-report-and-review-of-the-literature
#13
Joan How, Margaret Blattner, Susan Fowler, Andrea Wang-Gillam, Suzanne E Schindler
INTRODUCTION: There are increasing reports of posterior reversible encephalopathy syndrome (PRES) associated with the use of chemotherapeutic agents. Recognition of PRES is crucial given its reversibility with appropriate supportive management. We report a patient presenting with PRES after treatment with Rituximab, Cyclophosphamide, Hydroxydaunorubicin/Adriamycin, Oncovin/Vincristine, Prednisone (R-CHOP) and intrathecal methotrexate. We also perform a systematic review of the literature on chemotherapy-associated PRES...
November 2016: Neurologist
https://www.readbyqxmd.com/read/27799929/the-high-prevalence-of-functional-complement-defects-induced-by-chemotherapy
#14
Mischa P Keizer, Angela M Kamp, Cathelijn Aarts, Judy Geisler, Huib N Caron, Marianne D van de Wetering, Diana Wouters, Taco W Kuijpers
INTRODUCTION: To date, oncology patients are more dependent on non-cellular host defense against pathogens due to intensive (chemo)therapy-related bone marrow suppression. Since data on complement functionality in oncology patients are limited, we aimed to investigate the innate complement function in relation to the type of malignancy and therapy in a longitudinal cohort of patients. METHODS: A large single-center, prospective non-intervention study was conducted, in which blood samples were taken from patients before, during, and after treatment with chemotherapy and/or subsequent admittance for (febrile) neutropenia...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27790699/chemotherapeutic-intensity-and-survival-differences-in-young-patients-with-diffuse-large-b-cell-lymphoma-a-swedish-lymphoma-registry-study
#15
Christopher M Melén, Gunilla Enblad, Kristina Sonnevi, Henna Riikka Junlén, Karin E Smedby, Mats Jerkeman, Björn Engelbrekt Wahlin
Young patients with diffuse large B-cell lymphoma (DLBCL) are variably treated with rituximab combined with cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP), CHOP-etoposide (R-CHOEP), and anthracycline-based regimens with the addition of high-dose cytarabine/methotrexate (R-HDA/M). Using the nationwide, population-based Swedish Lymphoma Registry, we evaluated outcome, by treatment and Healthcare Region, in all 751 DLBCL patients aged ≤60 years without central nervous involvement, diagnosed in Sweden between 2007 and 2012...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27784356/-clinicopathologic-characteristics-and-outcome-of-isolated-ovarian-relapse-in-adolescent-with-acute-lymphoblastic-leukemia
#16
Ya-Ping Yu, Ping Song, Jian-Gang Mei, Zhi-Ming An, Xiao-Gang Zhou, Feng Li, Li-Ping Wang, Yu-Mei Tang, Yong-Ping Zhai
OBJECTIVE: To investigate the clinicopathologic characteristics,diagnosis and treatment of isolated ovarian relapse of acute lymphoblastic leukemia(ALL). METHODS: A 16-year-old girl presented with complaints of bone and joint pain. The peripheral blood and bone marrow(BM) smears showed 32% and 72% blasts, respectively, which were myeloperoxidase-negative. The blasts were positive for HLA-DR, TdT, CD10, CD19, CD22 and cCD79a and negative for CD34, CD5, CD7, CD13, CD33, CD56 and MPO detected by flow cytometry...
October 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27781293/methotrexate-elimination-and-toxicity-mthfr-677c-t-polymorphism-in-patients-with-primary-cns-lymphoma-treated-with-high-dose-methotrexate
#17
Yun Jung Choi, Hyangmin Park, Ji Sung Lee, Ju-Yeon Lee, Shin Kim, Tae Won Kim, Jung Sun Park, Jeong Eun Kim, Dok Hyun Yoon, Cheolwon Suh
The genetic association of the methylenetetrahydrofolate reductase gene (MTHFR) 677C>T polymorphism with methotrexate (MTX)-associated toxicity has been evaluated and conflicting results have been reported. The substantial heterogeneity of the studied population was suggested to be a possible explanation because ethnicity, MTX dose, coadministered chemotherapeutic agents, and folinate rescue dosage regimen could alter the MTX toxicity profile. The patient population was homogenized by limiting the cancer type to primary central nervous system lymphoma and chemotherapy protocol to a high-dose MTX monotherapy regimen...
October 25, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27779157/delayed-high-dose-methotrexate-excretion-and-influencing-factors-in-osteosarcoma-patients
#18
Wei Zhang, Qing Zhang, Ting-Ting Zheng, Jian-Cun Zhen, Xiao-Hui Niu
BACKGROUND: High-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is "gold standard" therapy for osteosarcoma. Plasma concentrations of methotrexate (MTX) are closely related to its efficacy and toxicity. Delayed excretion of MTX can lead to serious adverse reactions that may result in treatment cessation, irreversible organ damage, and death. This study focused on the incidence of delayed excretion of MTX in Chinese osteosarcoma patients. METHODS: A total of 1277 osteosarcoma patients were treated with HD-MTX chemotherapy (4291 cycles) from 2010 to 2015...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27752883/promising-treatment-results-with-blood-brain-barrier-disruption-bbbd-based-immunochemotherapy-combined-with-autologous-stem-cell-transplantation-asct-in-patients-with-primary-central-nervous-system-lymphoma-pcnsl
#19
Hanne Kuitunen, Susanna Tokola, Topi Siniluoto, Matti Isokangas, Eila Sonkajärvi, Seppo Alahuhta, Taina Turpeenniemi-Hujanen, Esa Jantunen, Tapio Nousiainen, Kaija Vasala, Outi Kuittinen
Primary central nervous system lymphoma (PCNSL) is a rare brain tumour with a dismal prognosis. Several phase II studies with high-dose methotrexate-based regimens have shown promising early results, but in all hospital-based data published so far, the disease outcome has been poor. Patients with relapsed or refractory disease have a dismal prognosis. We performed retrospective analysis to evaluate results and tolerabilities of BBBD therapy in combination with high-dose therapy supported by autologous stem cell transplantation...
October 17, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27748083/peficitinib-a-jak-inhibitor-in-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-in-methotrexate-inadequate-responders
#20
A J Kivitz, S R Gutierrez-Ureña, J Poiley, M C Genovese, R Kristy, K Shay, X Wang, J P Garg, A Zubrzycka-Sienkiewicz
OBJECTIVE: To evaluate efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to MTX. METHODS: In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (N=378) were treated with peficitinib 25 mg, 50 mg, 100 mg, 150 mg + MTX, or matching placebo + MTX once daily for 12 weeks (NCT01554696)...
October 16, 2016: Arthritis & Rheumatology
keyword
keyword
91529
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"